The size of the Global Cancer Metabolism Based Therapeutics market is set to grow at a brisk pace during the forecast period.
The hike in this market is driven by several factors, some of them include an increase in the number of people who are diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiations, heredity, chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries. Around 3% of the cancer cases and 7% of cancer-related deaths in the U.S. are attributed to pancreatic cancer.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Drug Type, Therapy, Indication and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health. |
This research report on the Global Cancer Metabolism Based Therapeutics Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2025.
Cancer Metabolism Based Therapeutics Market Analysis – By Therapy:
Cancer Metabolism Based Therapeutics Market Analysis – By Drug Type:
On the basis of drug type, the CPI-613 was introduced recently in 2018 which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from the American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer and around 43 thousand of them are experiencing a threat to their lives.
Cancer Metabolism Based Therapeutics Market Analysis – By Indication:
Around twenty-one thousand cases of Acute Myeloid Leukemia attacks were reported by the American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people and increased awareness about the symptoms and treatment process of pancreatic cancer which is helping the market to increase its size.
Regional Analysis:
As the number of people suffering from pancreatic cancer is high in North America, the North America Cancer Metabolism Based Therapeutics Market is dominating the Global Market. As there are increasing cases of cancer every year in developing countries like India and China, the potential for market expansion is high in these countries.
List of key market participants leading the Global Cancer Metabolism Based Therapeutics Market profiled in this report are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapy
5.1.1 Introduction
5.1.2 Biological Drug Therapies
5.1.3 Targeted Drug Therapies
5.1.4 Y-o-Y Growth Analysis, By Therapy
5.1.5 Market Attractiveness Analysis, By Therapy
5.1.6 Market Share Analysis, By Therapy
5.2 Drug Type
5.2.1 Introduction
5.2.2 Enasidenib
5.2.3 CPI-613
5.2.4 Other Drugs
5.2.5 Y-o-Y Growth Analysis, By Drug Type
5.2.6 Market Attractiveness Analysis, By Drug Type
5.2.7 Market Share Analysis, By Drug Type
5.3 Indication
5.3.1 Introduction
5.3.2 Melanoma
5.3.3 Myelodyspalstic Syndrome (MDS)
5.3.4 Acute Myeloid Leukemia (AML)
5.3.5 Metastatic Renal Cell Carcinoma
5.3.6 Others
5.3.7 Y-o-Y Growth Analysis, By Indication
5.3.8 Market Attractiveness Analysis, By Indication
5.3.9 Market Share Analysis, By Indication
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapy
6.1.3.3 By Drug Type
6.1.3.4 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapy
6.1.4.3 By Drug Type
6.1.4.4 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapy
6.1.5.3 By Drug Type
6.1.5.4 By Indication
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AstraZeneca
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis
8.3 Celgene
8.4 Rafael Pharmaceuticals
8.5 Cornerstone Pharmaceuticals
8.6 Polaris Group
8.7 Agios Pharmaceuticals
8.8 Taiho Pharmaceuticals
8.9 3-V Biosciences
8.10 Calithera Biosciences
8.11 BERG Health
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Request Sample Market Brochure to avail List of Tables and Figures of the report.
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
